The British company Semarion Ltd and US start-ups n6 Tec Inc and Portal Biotechnologies Inc were honoured with the New Product Award at the SLAS Conference 2025 in San Diego. The award, presented by the Society for Automation & Drug Screening, recognises pioneering technologies with the potential to transform the industry.

Italian InSimili Srl has been awarded the Ignite Award for the most innovative start-up company in the lab automation sector. The US$5,000 prize was presented by the Society for Laboratory Automation and Screening (SLAS) to the company at SLAS 2025, the leading international conference for lab automation and drug screening

On the second day of SLAS 2025, the world’s largest laboratory automation conference in San Diego, the last two finalists of the Ignite Award pitched their business models. Meanwhile, the 10 finalists of the SLAS New Product Award showcased their systems in the Innovation AveNEW area of the exhibition.

Denmark’s complement system activator specialist Commit Biologics A/S has added  a €5.5m extension to its €16.5 seed financing. New investor Korys joined Novo Holdings and Bioqube Ventures.

The world’s most important conference for laboratory automation and drug screening tools, SLAS 2025 International, opens today in San Diego. One of the highlights will be the pitches for the best start-up, the SLAS Ignite Award. European Biotechnology has taken a look at the technologies for you in advance.

Nippon Shinyaku has secured an option to acquire exclusive US rights to commercialize AB2 Bio’s tadekinig alfa to treat primary monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 mutation and XIAP deficiency.

Berlin-based food tech start-up Project Eaden is prepared to launch its first plant-based ham product by mid-year in 2,000 REWE supermarkets. A oversubscribes Series A financing laid the basis for this success

Paris-based drug delivery specialist Ceres Brain Therapeutics SA has raised €6m led by ANJAC, a French family-owned industrial group and preferred partner of healthcare laboratories and beauty and well-being brands, to support the clinical development neurological treatments.

Iceland’s Arctic Therapeutics has secured €26.5m in a Series A financing aimed to push its oral drug candidates AT-O01 and AT-004 into clinical trails in patients with rare amyloid aggregation diseases including Alzheimer’s disease.

EuropaBio calls for an ambitious cross-sectoral EU Biotech Act, that strengthens Europe as a global biotechnology leader for competitiveness and strategic autonomy.